Gabather AB Logo

Gabather AB

Developing novel GABAA receptor drugs for neuropsychiatric disorders.

GABA | ST

Overview

Corporate Details

ISIN(s):
SE0010869552 (+1 more)
LEI:
549300VLUOMD0TE1O093
Country:
Sweden
Address:
FORSKARGATAN 20 J, 151 36 Södertälje
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Gabather AB is a clinical-stage pharmaceutical company, founded in 2014, that develops novel therapeutics for neuropsychiatric disorders. The company's approach focuses on proprietary drug candidates that modulate the GABAA receptor system to restore balance in the brain and enhance cognitive function. Its primary focus areas include anti-psychotics, anti-depressants, anxiolytics, analgesics, and cognition-enhancing treatments for conditions such as Alzheimer's disease. Gabather's lead drug candidate, GT-002, has completed Phase I clinical trials, showing excellent pharmacokinetics and a strong safety profile. The company's development projects are based on over a decade of research from Lund University and the Research Institute of Biological Psychiatry in Roskilde.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Gabather AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Gabather AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Gabather AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

DiaMedica Therapeutics Inc. Logo
Developing a novel protein therapy for acute ischemic stroke and preeclampsia.
United States of America
DMAC
Diamyd Medical AB (publ) Logo
Developing precision immunotherapies to preserve insulin in autoimmune diabetes.
Sweden
DMYD
Dianthus Therapeutics, Inc. /DE/ Logo
Developing selective antibody therapies for severe autoimmune diseases.
United States of America
DNTH
Diasorin Logo
Develops immunodiagnostic and molecular diagnostic kits and systems for healthcare and research.
Italy
DIA
Disc Medicine, Inc. Logo
Developing novel therapies for patients with serious hematologic and rare blood disorders.
United States of America
IRON
DONG-A ST CO.,LTD Logo
Develops and distributes ethical drugs, medical devices, and diagnostics for global healthcare.
South Korea
170900
DongKoo Bio & Pharma Co., Ltd. Logo
Pharma leader in dermatology, developing treatments, probiotics, and investing in biotech therapies.
South Korea
006620
DongKook Life Science Co., Ltd. Logo
A pharmaceutical firm specializing in contrast media for diagnostic imaging and medical devices.
South Korea
303810
DongKookPharmaceuticalCo.,Ltd. Logo
Develops, manufactures, and distributes pharmaceuticals and healthcare products globally.
South Korea
086450
DONGSUNG PHARMACEUTICAL CO.,LTD Logo
A Korean firm making pharmaceuticals, cosmetics, and popular hair care products for over 60 years.
South Korea
002210

Talk to a Data Expert

Have a question? We'll get back to you promptly.